A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 With a Long Term Double-Blind Extension in Subjects With Mild to Moderate Alzheimer's Disease (Protocol No. MK-8931-017-10)(Also Known as SCH 900931, P07738)
Latest Information Update: 10 May 2022
At a glance
- Drugs Verubecestat (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms EPOCH
- Sponsors Merck & Co; Merck Sharp & Dohme
- 10 Jan 2022 New source identified and integrated (Japan Pharmaceutical Information Center - Clinical Trials Information record: JapicCTI132229).
- 17 Mar 2019 This trial has been completed in UK - MHRA (End date-2017-04-14), according to European Clinical Trials Database.
- 03 May 2018 This trial was terminated early for futility 50 months after onset, which was within 5 months before its scheduled completion, and after enrollment of the planned patients was complete, according to results published in the New England Journal of Medicine.